[go: up one dir, main page]

WO2000041463A3 - Combination of hepatitis b vaccine with antiviral agents - Google Patents

Combination of hepatitis b vaccine with antiviral agents Download PDF

Info

Publication number
WO2000041463A3
WO2000041463A3 PCT/EP1999/010295 EP9910295W WO0041463A3 WO 2000041463 A3 WO2000041463 A3 WO 2000041463A3 EP 9910295 W EP9910295 W EP 9910295W WO 0041463 A3 WO0041463 A3 WO 0041463A3
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
vaccine
combination
antiviral agents
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1999/010295
Other languages
French (fr)
Other versions
WO2000041463A2 (en
Inventor
Gillian Frances Atkinson
Ronald James Boon
Pierre G Vandepapeliere
Martine Anne Cecil Wettendorff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU21009/00A priority Critical patent/AU760574B2/en
Priority to JP2000593088A priority patent/JP2002534438A/en
Priority to KR1020017008833A priority patent/KR20010090011A/en
Priority to PL99349347A priority patent/PL349347A1/en
Priority to BR9916893-6A priority patent/BR9916893A/en
Priority to IL14418699A priority patent/IL144186A0/en
Priority to EP99965531A priority patent/EP1140163A2/en
Priority to CA002359110A priority patent/CA2359110A1/en
Priority to HK02101211.9A priority patent/HK1041434A1/en
Priority to HU0105070A priority patent/HUP0105070A2/en
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Priority to NZ512890A priority patent/NZ512890A/en
Publication of WO2000041463A2 publication Critical patent/WO2000041463A2/en
Publication of WO2000041463A3 publication Critical patent/WO2000041463A3/en
Priority to NO20013337A priority patent/NO20013337L/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention provides a pharmaceutical pack comprising as active ingredients (1) an antiviral agent active against hepatitis B virus and (2) a vaccine for the prophylaxis and/or treatment of hepatitis B infection, the active ingredients being for simultaneous or sequential use. Preferred components are a nucleoside analogue as the antiviral agent, together with a hepatitis B virus vaccine which comprises a hepatitis B virus surface antigen.
PCT/EP1999/010295 1999-01-12 1999-12-21 Combination of hepatitis b vaccine with antiviral agents Ceased WO2000041463A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
HK02101211.9A HK1041434A1 (en) 1999-01-12 1999-12-21 Combination of hepatitis b vaccine with antiviral agents
KR1020017008833A KR20010090011A (en) 1999-01-12 1999-12-21 Novel treatment
PL99349347A PL349347A1 (en) 1999-01-12 1999-12-21 Novel treatment
BR9916893-6A BR9916893A (en) 1999-01-12 1999-12-21 Treatment
IL14418699A IL144186A0 (en) 1999-01-12 1999-12-21 Novel treatment
EP99965531A EP1140163A2 (en) 1999-01-12 1999-12-21 Combination of hepatitis b vaccine with antiviral agents
CA002359110A CA2359110A1 (en) 1999-01-12 1999-12-21 Combination of hepatitis b vaccine with antiviral agents
AU21009/00A AU760574B2 (en) 1999-01-12 1999-12-21 Novel treatment
JP2000593088A JP2002534438A (en) 1999-01-12 1999-12-21 New treatment
HU0105070A HUP0105070A2 (en) 1999-01-12 1999-12-21 Novel treatment
NZ512890A NZ512890A (en) 1999-01-12 1999-12-21 Antiviral agents including nucleoside analogues active against hepatitis B virus (HBV)
NO20013337A NO20013337L (en) 1999-01-12 2001-07-05 New treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9900630.6 1999-01-12
GB9900630 1999-01-12

Publications (2)

Publication Number Publication Date
WO2000041463A2 WO2000041463A2 (en) 2000-07-20
WO2000041463A3 true WO2000041463A3 (en) 2000-11-09

Family

ID=10845878

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/010295 Ceased WO2000041463A2 (en) 1999-01-12 1999-12-21 Combination of hepatitis b vaccine with antiviral agents

Country Status (19)

Country Link
EP (1) EP1140163A2 (en)
JP (1) JP2002534438A (en)
KR (1) KR20010090011A (en)
CN (1) CN1391482A (en)
AR (1) AR022250A1 (en)
AU (1) AU760574B2 (en)
BR (1) BR9916893A (en)
CA (1) CA2359110A1 (en)
CO (1) CO5241355A1 (en)
CZ (1) CZ20012544A3 (en)
HK (1) HK1041434A1 (en)
HU (1) HUP0105070A2 (en)
IL (1) IL144186A0 (en)
NO (1) NO20013337L (en)
NZ (1) NZ512890A (en)
PL (1) PL349347A1 (en)
TR (1) TR200102024T2 (en)
WO (1) WO2000041463A2 (en)
ZA (1) ZA200105690B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE335510T1 (en) 1998-05-22 2006-09-15 Ottawa Health Research Inst METHODS AND PRODUCTS FOR INDUCING MUCOSA IMMUNITY
PT1103564E (en) 1998-07-31 2009-03-13 Int Inst Cancer Immunology Inc CANCER ANTIGENS BASED ON WT1 TUMOR SUPPRESSOR GENE PRODUCT
US20040097703A1 (en) 2001-03-22 2004-05-20 Haruo Sugiyama Wt1 modified peptide
WO2003028757A1 (en) * 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
JPWO2003028758A1 (en) * 2001-09-28 2005-01-13 治夫 杉山 Method for inducing antigen-specific T cells
TWI275392B (en) * 2002-04-08 2007-03-11 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
MXPA05004588A (en) 2002-10-29 2005-12-14 Coley Pharmaceutical Group Ltd Use of cpg oligonucleotides in the treatment of hepatitis c virus infection.
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
CN100443117C (en) * 2003-05-13 2008-12-17 深圳康泰生物制品股份有限公司 Hepatitis B treating vaccine prepn and its prepn process and use
US8541167B2 (en) 2004-06-03 2013-09-24 Saint Louis University Methods and compositions for vaccination
WO2008104133A1 (en) * 2007-02-28 2008-09-04 Centro De Ingeniería Genética Y Biotecnología Combination therapy for the treatment of chronic hepatitis b
US12409221B2 (en) * 2018-12-24 2025-09-09 Grand Theravac Life Sciences (Nanjing) Co., Ltd. Pharmaceutical preparation for treating hepatitis b, preparation method therefor and use thereof
JPWO2022215737A1 (en) * 2021-04-07 2022-10-13

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0414374A2 (en) * 1989-07-25 1991-02-27 Smithkline Biologicals S.A. Novel antigens and methods for their preparation
WO1999045957A2 (en) * 1998-03-09 1999-09-16 Smithkline Beecham Biologicals S.A. Combined vaccine compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0414374A2 (en) * 1989-07-25 1991-02-27 Smithkline Biologicals S.A. Novel antigens and methods for their preparation
WO1999045957A2 (en) * 1998-03-09 1999-09-16 Smithkline Beecham Biologicals S.A. Combined vaccine compositions

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BERENGUER M ET AL: "Hepatitis B and C viruses: Molecular identification and targeted antiviral therapies", PROCEEDINGS ASSOCIATION OF AMERICAN PHYSICIANS, vol. 110, no. 2, March 1998 (1998-03-01), pages 98 - 112, XP000909240 *
BONI C ET AL: "Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B [see comments].", JOURNAL OF CLINICAL INVESTIGATION, (1998 SEP 1) 102 (5) 968-75., XP000909082 *
GROB P J: "Hepatitis B: virus, pathogenesis and treatment", VACCINE,GB,BUTTERWORTH SCIENTIFIC. GUILDFORD, vol. 16, no. 1001, November 1998 (1998-11-01), pages S11 - S16, XP004150417, ISSN: 0264-410X *
MOLLOY P J ET AL: "Combined interferon, famciclovir and GM-CSF treatment of HBV infection in an individual with periarteritis nodosa.", HEPATO-GASTROENTEROLOGY, (1999 JUL-AUG) 46 (28) 2529-31., XP000909277 *
PIANKO S. ET AL: "Chronic hepatitis B: New therapies on the horizon?.", LANCET, (13 NOV 1999) 354/9191 (1662-1663)., XP000906960 *
RUDD, JENNIFER N. (1) ET AL: "Possible role for hepatitis B vaccine after lamivudine rescue for severe acute hepatitis B.", GASTROENTEROLOGY, (APRIL, 1999) VOL. 116, NO. 4 PART 2, PP. A1268. MEETING INFO.: DIGESTIVE DISEASE WEEK AND THE 100TH ANNUAL MEETING OF THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION ORLANDO, FLORIDA, USA MAY 16-19, 1999 AMERICAN GASTROENTEROLOGICAL A, XP000909262 *
SUK-FONG LOK A.: "Hepatitis B infection: Pathogenesis and management.", JOURNAL OF HEPATOLOGY, SUPPLEMENT, (2000) 32/1 (89-97)., XP000909278 *
VALDEZ H ET AL: "Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group.", AIDS, (2000 JAN 7) 14 (1) 11-21., XP000909260 *

Also Published As

Publication number Publication date
KR20010090011A (en) 2001-10-17
NO20013337D0 (en) 2001-07-05
WO2000041463A2 (en) 2000-07-20
TR200102024T2 (en) 2001-12-21
AR022250A1 (en) 2002-09-04
CO5241355A1 (en) 2003-01-31
JP2002534438A (en) 2002-10-15
PL349347A1 (en) 2002-07-15
AU2100900A (en) 2000-08-01
HUP0105070A2 (en) 2002-04-29
ZA200105690B (en) 2002-09-25
BR9916893A (en) 2001-11-20
HK1041434A1 (en) 2002-07-12
CZ20012544A3 (en) 2002-01-16
NO20013337L (en) 2001-08-17
NZ512890A (en) 2003-09-26
CA2359110A1 (en) 2000-07-20
CN1391482A (en) 2003-01-15
EP1140163A2 (en) 2001-10-10
IL144186A0 (en) 2002-05-23
AU760574B2 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
RS20120201A3 (en) Methods and compositions for hepatitis c virus treatment
CA2253490A1 (en) Use of il-12 and ifn-.alpha. for the treatment of infectious diseases
DE60030293D1 (en) UREA-SUBSTITUTED IMIDAZOCHINOLINE
BR0111195A (en) Use of b-1,2'-deoxy-nucleosides in the treatment of hepatitis delta virus infection
IL215891A (en) Hepatitis c virus serine protease inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment of hepatitis c virus infections
CA2434386A1 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2000041463A3 (en) Combination of hepatitis b vaccine with antiviral agents
IL139002A0 (en) Compositions for the treatment of hiv and other viral infections
HUP0300121A3 (en) Macrocyclic peptides active against the hepatitis c virus, process for preparation and pharmaceutical compositions containing them
AU1262001A (en) Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
GEP20104960B (en) USE OF [D-MeALa]3-[EtVal]4-CYCLOSPORIN FOR THE TREATMENT OF HEPATITIS C INFECTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAID [D-MeAla]3-[EtVal]4-CYCLOSPORIN
WO2003051306A3 (en) N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
WO2002092006A3 (en) Nucleic acid-based compounds and methods of use thereof
WO2001010456A3 (en) Peptides that block viral infectivity and methods of use thereof
GB0029936D0 (en) A pharmaceutical formulation suitable for the treatment of hepititis B, hepititis C and other viral infections of the liver and a process for its preparation
EA200100494A3 (en) Synthesis, anti-human immunodeficiency virus and anti-hepatitis b virus activities of 1,3-oxaselenolane nucleosides
AU2002219881A1 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
ZA991029B (en) Composition and methods for treatment of hiv infections.
HUP0100087A3 (en) Nucleosides analogues, the use thereof for producing medicaments useful against retroviral infections and hepatitis b virus and the same medicaments
WO1999051256A3 (en) Use of l-glu-l-trp in the treatment of hiv infection
HK1041444A1 (en) Pharmaceutical compositions comprising peg-asparaginase for the treatment of hiv infections
AU2002323443A1 (en) Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
ATE282430T1 (en) ANTIVIRAL PHARMACEUTICAL COMPOSITIONS CONTAINING IRON CHELATOR
ZA200108398B (en) Anti-HIV-1 vaccine comprising all or part of the HIV-1 Tat protein.
WO2004064784A3 (en) Composition and method for preventing or treating a virus infection

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99816471.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2000 593088

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 144186

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1999965531

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2359110

Country of ref document: CA

Ref document number: 2359110

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 21009/00

Country of ref document: AU

Ref document number: IN/PCT/2001/969/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 512890

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1020017008833

Country of ref document: KR

Ref document number: PA/a/2001/007112

Country of ref document: MX

Ref document number: PV2001-2544

Country of ref document: CZ

Ref document number: 2001/02024

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 09869998

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999965531

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017008833

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2001-2544

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 21009/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999965531

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020017008833

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV2001-2544

Country of ref document: CZ